OBJECTIVES: E-STAR is an ongoing, international, observational survey evaluating long-term clinical and economic outcomes in patients switched to a new antipsychotic. METHODS: Data are collected via a secured web-based system, retrospectively for 12-months and prospectively for two-years. Patient demographics, treatment and hospitalisation history, reason for initiating new treatment, Clinical Global Impression-Severity (CGI-S), Global Assessment of Functioning (GAF) and adverse event data are collected. RESULTS: Complete baseline and retrospective data are currently available for 1920 patients enrolled: Germany (n = 744), Spain (n = 709), Australia (n = 467). Patients reported here switched to long acting injectable (LAI) risperidone Mean age was 39.5 years (SD 11.8; range 37.5-41); majority were male (mean 61%; range 56-70%). 98% had a diagnosis of schizophrenia or schizoaffective disorder (range 98-100%). Mean duration of illness was 10.8 years (SD 9.3; range 9.2-12.6 years). Majority of patients (>80%) at baseline had a CGI-S score of 4-6 indicating that patients were moderately (35%), markedly (34%) or severely (18%) ill. The GAF scores were similar across countries (mean 46; SD 15; range 43-48). There were country differences in hospitalisation history during the 12month retrospective period: 28%, 70%, and 17% of patients in Germany, Spain and Australia respectively had no hospitalisations; for patients with hospitalisations, the mean number of days hospitalised per patient was 58.2 (SD 53.1), 38.3 (SD 51.1), and 66.9 (SD 90.3) respectively. Prior to the switch to (LAI) risperidone, 67-90% patients were taking oral atypicals, 27-35% oral conventionals, and 22-52% depot conventionals. The most frequent reason for switching was compliance: Germany (37%), Australia (52%), Spain (30%). CONCLU-SIONS: Compliance remains an important treatment issue even for those treated with atypicals. Continued enrollment, and follow-up will enable a better understanding of a broader range of treatment patterns in schizophrenic patients
Farmer D 1 , Ingham M 2 , Jacobs A 3 1 Interactive Educational Systems, Ltd, Hampton Court, Surrey, UK; 2 Johnson & Johnson Pharmaceutical Services, Raritan, NJ, USA; 3 Janssen Pharmaceutica, Beerse, Belgium OBJECTIVES: E-STAR is an international, non-interventional, observational study of clinical and economic outcomes in schizophrenia/schizoaffective patients who switch to a new antipsychotic. METHODS: Data over a 12-month retrospective and 24 month prospective period from in-or out-patients who start on a new antipsychotic medication are collected via a secure, privacy-protected web-site. All data are automatically checked against validation rules at the point of entering the study. The validation rules are established in consultation with specialists in data analysis and key opinion leaders, and are designed to prevent missing data, duplicate data and data outside preestablished, reasonable ranges. These require confirmation by the physician before the system will accept them. If data is entered incorrectly, the physician submits correction requests via an audited online data change request system. A further supplemental audit process is used to control quality of uploaded data. This process uses monthly reports to identify potential inconsistencies within the dataset after data has been validated at entry. RESULTS: Uploaded data undergoing quality control checks, requiring adjustment by physicians, is minimal. Audit reports have helped redress data entry training issues, further enhancing data accuracy. Analysis is only conducted on patients after resolution of outstanding supplemental data queries. Conclusion: This largely automated three stage quality control process is important to the implementation of non-interventional, observational research such as this, where the goal is to study outcomes in a generalisable, representative patient cohort. This permits the inclusion of patients from a broad geographic region, which will add significantly to our understanding of the use of anti-psychotics in actual clinical practice, outside of the influence of clinical trial settings. This also allows for much faster analysis and presentation of robust, pragmatic outcomes data.
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COMPARISON OF OUTCOMES REPORTED BY INDIVIDUALS WITH SCHIZOPHRENIA RESIDING IN THE COMMUNITY AND OBJECTIVE OUTCOMES REPORTED BY CAREGIVERS
Barr J, Schumacher G, Ohman S, Mason E Northeastern University, Boston, MA, USA OBJECTIVES: Compare patient-and caregiver-reported outcomes on 25 objective questions contained within the 51-item Schizophrenia Outcomes Assessment Project (SOAP) quality of life survey. METHODS: In total, 1500 community-residing individuals with schizophrenia in five states (Massachusetts, South Carolina, Wisconsin, Arizona, Washington) completed SOAP-51 survey at baseline and weeks four, five, and 12. Previously, factor analysis indicated that SOAP-51 had eight factors (satisfaction, self concept, work/role, mental health, interpersonal, medication effects, activities of daily living, and physical function) with Cronbach alphas ranging from 0.728-0.937 and test/retest intraclass correlations >0.70 for all but one factor. An expert panel identified 25 SOAP items that could be objectively measured. This 25-item subset was given to each patient's primary caregiver concurrent with each patient's SOAP-51 administration. Caregivers were asked to answer each item in two ways: 1) What is your objective response?; and 2) What do you think is the patient's response? Three correlation sets were performed for week-four responses: a) caregiver's objective responses compared to caregiver's estimation of patient's responses ( . Physical function factor correlations were the strongest in Correlation A (0.862), but the lowest in Correlation B (-0.292) and C (-0.353). CONCLUSIONS: Caregiver objective assessments of individuals with schizophrenia can vary markedly from patientreported outcomes, but asking caregivers to view the world through the eyes of the patient closes this gap. Asking caregivers
